Welcome to our dedicated page for HEMAB THERAPEUTICS HOLDINGS news (Ticker: COAG), a resource for investors and traders seeking the latest updates and insights on HEMAB THERAPEUTICS HOLDINGS stock.
Hemab Therapeutics Holdings reports corporate and clinical-stage biotechnology developments tied to its blood coagulation disorder programs. Company news includes its Nasdaq listing and initial public offering, capital-structure updates, shareholder voting matters, and clinical or regulatory disclosures related to rare bleeding disorder therapeutics.
Updates for COAG also center on Hemab's development focus, including sutacimig (HMB-001), a bispecific antibody program for prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency.
Hemab Therapeutics (Nasdaq: COAG), a clinical-stage biotech focused on blood coagulation disorders, will participate in the 2026 Jefferies Global Healthcare Conference in New York.
A fireside chat is scheduled for Thursday, June 4, 2026 at 9:20 AM ET, with a live webcast and replay available on Hemab’s investor website.
Hemab Therapeutics (Nasdaq:COAG) reported Q1 2026 results and outlined clinical and financing milestones.
The company completed an upsized IPO in May 2026, raising $346.7 million gross, received FDA Breakthrough Therapy Designation for sutacimig in Glanzmann thrombasthenia, advanced multiple trials, and ended Q1 with $163.5 million in cash and securities.
Hemab Therapeutics (Nasdaq: COAG) closed its upsized initial public offering on May 4, 2026, selling 19,262,500 shares at $18.00 per share, including 2,512,500 shares from full exercise of the underwriters' option. Gross proceeds were approximately $346.7 million.
The company’s common stock began trading on the Nasdaq Global Select Market on May 1, 2026 under ticker COAG. A registration statement was declared effective April 30, 2026.
Hemab Therapeutics (Nasdaq: COAG) priced an upsized initial public offering of 16,750,000 shares at $18.00 per share, with a 30-day underwriter option for an additional 2,512,500 shares.
Gross proceeds are expected to be approximately $301.5 million before underwriting discounts, and trading on the Nasdaq Global Select Market is expected to begin on May 1, 2026 with closing on or about May 4, 2026.